ZURICH (Thomson Financial) - Newron Pharmaceuticals SAPA narrowed its first half net loss to 3.975 mln eur from 9.922 mln in the year-earlier period as partner Merck Serono either directly paid development costs or reimbursed these for the development of sleeping drug safinamide.
